Zensita 100 Tablet contains Sitagliptin 100 mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin works by enhancing the levels of incretin hormones, which increase insulin synthesis and release from pancreatic beta cells and decrease glucagon secretion from alpha cells, thereby improving glycemic control. Zensita 100 is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The medication is generally well-tolerated, with a low risk of hypoglycemia when used alone. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Zensita 100 should be used under medical supervision, with regular monitoring of blood glucose levels and renal function. It is not indicated for type 1 diabetes or diabetic ketoacidosis. Patient adherence to lifestyle modifications alongside pharmacotherapy is essential for optimal therapeutic outcomes.